Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSome people starting semaglutide (Wegovy) notice a dip in sex drive, and it's a question worth taking seriously. Low libido during weight-loss treatment can have several overlapping causes, most of which have nothing to do with the medicine itself. Understanding those causes is the first step to deciding what, if anything, to do about it. Wegovy is a prescription-only medicine; a prescriber reviews your full picture before and during treatment, which is exactly the right place to raise this.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The honest answer is: probably not in the way you might fear. The large STEP 1 trial, published in the New England Journal of Medicine, tracked a broad range of outcomes across 68 weeks in adults taking semaglutide 2.4mg. Reduced libido was not among the adverse effects that emerged at a statistically notable rate compared with placebo. That doesn't mean no one experiences it, individual responses vary, and clinical trials don't capture everything. But it does mean semaglutide isn't thought to act on sex hormones or desire pathways in a direct, predictable way, and you can read more about what semaglutide is and how it works if you'd like a clearer foundation before going further.
The more likely culprits are indirect. GLP-1 medicines slow gastric emptying and frequently cause nausea, especially in the first weeks or after a dose step-up. Feeling persistently queasy is not a condition that tends to coincide with feeling amorous. The same goes for fatigue, which is listed among the common side effects on the NHS semaglutide medicines page. If your body is directing energy toward adapting to a new medicine and a reduced calorie intake, libido is often the first thing to quietly step aside. That's a human response, not a pharmacological one.
There's also the reality of rapid early weight loss itself. The body registers significant change quickly, and hormone levels can shift in ways that affect mood and desire. This tends to settle as weight stabilises.
Before deciding whether to raise this with a prescriber, change anything about your treatment, or simply wait, it helps to map out which factors apply to you. Three are worth working through honestly.
First: timing. Did the dip in libido start precisely when you began Wegovy, or when you moved to a higher dose? A tight correlation with the medicine is worth noting. If it predates Wegovy, or has been building for months alongside other life pressures, the medicine may be coincidental. You can explore the relationship between low energy and Wegovy more closely, since fatigue and low libido so often travel together.
Second: other symptoms. Low libido that comes packaged with low mood, poor sleep, or unusual physical symptoms may point toward something that warrants its own attention regardless of treatment. For women specifically, hormonal factors (perimenopause, thyroid changes, contraception type) interact with weight-loss treatment in ways that can affect desire. There's more on this in the context of how semaglutide relates to libido in women.
Third: the longer view. Many people find that three or four months into treatment, as nausea eases and energy returns, their sense of themselves (including their sex drive) actually improves. Obesity itself is strongly associated with lower libido, lower testosterone in men, and hormonal dysregulation more broadly. Weight loss, sustained over time, tends to reverse some of those effects, and our page on how Wegovy affects libido looks at this longer arc in more detail. Worth factoring in before drawing any conclusions.
If the dip is brief and clearly linked to early nausea or dose adjustment, the practical response is often to wait a few weeks and see whether it resolves. Most GI-related side effects of semaglutide ease once the body adjusts, and libido tends to follow. Eating enough protein, staying hydrated, and keeping activity going at a manageable level all help the adjustment phase feel less like a slog.
If it's persisting beyond six to eight weeks, is distressing, or is affecting your relationship or wellbeing, it's time to talk to a prescriber. Don't stop or adjust the medicine on your own, doses, timing and the question of whether to continue are clinical decisions. Our prescribers are available seven days a week for exactly this kind of aftercare question; if you're weighing up your treatment options more broadly, our treatment page explains what a consultation covers.
It's also worth reviewing whether anything else changed at the same time: a new contraceptive, a change in sleep pattern, a stressful period at work. A question our prescribers hear fairly regularly is whether the medicine or life is responsible, and the answer is almost always that it's worth ruling out the obvious things first.
For a fuller picture of how semaglutide interacts with libido and desire, the evidence on semaglutide and libido covers the research in more detail. And if you're curious about the broader side-effect and effectiveness picture for this medicine, the Wegovy overview is a good place to start.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.